Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sepracor-Looks very promising -- Ignore unavailable to you. Want to Upgrade?

To: Rocky9 who wrote (9625)	8/14/2006 3:02:07 PM
From: Iamarangerboy	Respond to of 10280

thanks... great help! does this account for the large drop in share price today? or is there another shoe to fall on the option deal.....

To: Rocky9 who wrote (9625)	8/15/2006 6:14:23 PM
From: ritzkid8	Read Replies (2) \| Respond to of 10280

Flat Lunesta rx's going on a year and the HFA trend is positive but not near enough. It will be interesting to see if the company will even hit its revised forecast for Lunesta? Hitting the number for Xopenex neb is no guarantee either, especially if the Medicare situation rears its ugly head. Other than a buyout/merger or an incredible in-licensing deal, the downward pressures on this stock are too much and it will eventually breakdown technically and fall into the $30's.